

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6883669

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MARK R. BAKER	11/27/2017
RECEIVING PARTY DATA		
Name:	PROGENICS PHARMACEUTICALS, INC.	
Street Address:	ONE WORLD TRADE CENTER, 47TH FLOOR SUITE J	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10007	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16938488
CORRESPONDENCE DATA		
Fax Number:	(617)502-5002	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	617-248-5000	
Email:	PatentDocket@choate.com	
Correspondent Name:	CHOATE HALL & STEWART LLP-PATENT DOCKET	
Address Line 1:	TWO INTERNATIONAL PLACE	
Address Line 4:	BOSTON, MASSACHUSETTS 02110	
ATTORNEY DOCKET NUMBER:	2010358-0189	
NAME OF SUBMITTER:	RONEN ADATO, PHD	
SIGNATURE:	/Ronen Adato/	
DATE SIGNED:	08/25/2021	
Total Attachments: 5		
source=EXI-005USCON3 Assignment#page1.tif		
source=EXI-005USCON3 Assignment#page2.tif		
source=EXI-005USCON3 Assignment#page3.tif		
source=EXI-005USCON3 Assignment#page4.tif		
source=EXI-005USCON3 Assignment#page5.tif		

COMBINED ASSIGNMENT & DECLARATION

A. ASSIGNMENT

WHEREAS, I, Mark R. Baker of New York, New York, am aware of the patent application entitled:

**NETWORK FOR MEDICAL IMAGE ANALYSIS, DECISION SUPPORT SYSTEM,
AND RELATED GRAPHICAL USER INTERFACE (GUI) APPLICATIONS; and**

☐ prepared for filing in the United States Patent and Trademark Office; or

☒ identified by United States Application Serial No. 15/794220
filed in the United States Patent and Trademark Office on; October 26, 2017; and

☒ identified by International Patent Application No. PCT/US17/58418
filed on October 26, 2017; and

☒ and is also aware of the following priority applications:

Serial No.	Filed
62/413,936	October 27, 2016

WHEREAS Progenics Pharmaceuticals, Inc. (hereinafter "ASSIGNEE"), having a usual place of business at One World Trade Center, 47th Floor Suite J, New York, New York 10007, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, I have sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. My sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such

patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by me had this sale, assignment and transfer not been made;

AND, I hereby acknowledge that this Assignment, being of my entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, I hereby further agree for myself and my executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts I know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, I further hereby authorize ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, I hereby appoint ASSIGNEE as my common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, I hereby request the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, I covenant with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by me, and that full right to convey the same as herein expressed is possessed by me.

B. DECLARATION (37 CFR 1.63)

As a below named inventor, I hereby declare that:

This declaration is directed to the patent application entitled:

**NETWORK FOR MEDICAL IMAGE ANALYSIS, DECISION SUPPORT SYSTEM,
AND RELATED GRAPHICAL USER INTERFACE (GUI) APPLICATIONS; and**

☐ attached hereto or prepared for filing in the United States Patent and Trademark Office; or

☒ identified by United States Application Serial No. 15/794220
filed in the United States Patent and Trademark Office on October 26, 2017; or


☐ identified by International Patent Application No. _____
filed on _____.

The above-identified application was made or authorized to be made by me.


I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

I have reviewed and understand the contents of the application, including the claims and am aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Signature: 
Mark R. Baker

Date: Nov. 27, 2017

Witness Signature: 

Date: Nov 27, 2017


Witness Name (printed): Kerry Fox

Witness Signature: 

Date: Nov 27 2017

Witness Name (printed): Lucia Alessi

The undersigned (whose title is supplied below) is authorized to act on behalf of Progenics Pharmaceuticals, Inc.

Signature:  Date: Nov 27, 2017
Name (printed): Mark R. Baker
Title (printed): Chief Executive Officer